reference/14146400

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14146400

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	304
issn	0007-0963
issueIdentifier	2
pageRange	296-304
publicationName	The British journal of dermatology
startingPage	296
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f2da86d6d3e72c92599511f85fbccbed
bibliographicCitation	Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S, Imayama S, Kato M, Hasebe I, Taira K, Yamamoto M, Mihara R, Kabashima K, Ruzicka T, Hanifin J, Kumagai Y. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb;174(2):296–304. doi: 10.1111/bjd.14207. PMID: 26409172.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfb2ded463ab916f6f97345af0d5a797 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a2b51e7f6900cc2f55b48507ff04152 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c372c8ba683f5078556ea35421e309db http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ae49145c11d28ea3ac7fb4c285c6619 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a3f427879400af32805066df7332e52 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_970e3b430331ca24bc68a6df95db8cd2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bcf41a153f25ee4b9de5774ff68ce9b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77eecfe012ddbfd5e11f3a6a4a9d80d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a4227115caf0252d567c17cc1067308 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d94d700273d82a84af8fe182c9e06152 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c617c7ab3ede3f0eeff42fbe2504771b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a934cfc259ef4ddd533ebd0055768988 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b85b2ab17a48688a7043e3df9110ba42 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d73b8aad8effdcc8467202974491817 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a9563b50b03f811a9954a6aac2dc02f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_496f33ac1ef0d264d6f51230712f44b9
date	2015-12-19^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/26409172 https://doi.org/10.1111/bjd.14207
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1793 https://portal.issn.org/resource/ISSN/0007-0963
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study
discusses	http://id.nlm.nih.gov/mesh/M000628116 http://id.nlm.nih.gov/mesh/M0487177 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0001333 http://id.nlm.nih.gov/mesh/M0027328
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000893Q000008 http://id.nlm.nih.gov/mesh/D003876Q000188 http://id.nlm.nih.gov/mesh/D061067Q000008 http://id.nlm.nih.gov/mesh/D018123Q000276
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D012893Q000209 http://id.nlm.nih.gov/mesh/D007279 http://id.nlm.nih.gov/mesh/D011537Q000188 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D061067Q000493 http://id.nlm.nih.gov/mesh/D000893Q000009 http://id.nlm.nih.gov/mesh/D064368 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D012893Q000188 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D000893Q000493 http://id.nlm.nih.gov/mesh/D016896
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID586 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID26133 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7433 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_334fdaa7cbe806e6380a4c04c39be210 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9251 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9b21e75df0e62cdf4cc4c4bb4c6225e2 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8995 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5754

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID252827378 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID178101692

Showing number of triples: 1 to 71 of 71.